Fideuram Asset Management Ireland dac Invests $10.12 Million in Regeneron Pharmaceuticals, Inc. $REGN

Fideuram Asset Management Ireland dac purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,111 shares of the biopharmaceutical company’s stock, valued at approximately $10,120,000. Regeneron Pharmaceuticals comprises about 0.7% of Fideuram Asset Management Ireland dac’s holdings, making the stock its 29th largest holding.

A number of other institutional investors also recently made changes to their positions in the business. National Pension Service boosted its stake in shares of Regeneron Pharmaceuticals by 29.8% in the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after purchasing an additional 82,853 shares in the last quarter. Basepoint Wealth LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $40,000. Rothschild Investment LLC boosted its stake in shares of Regeneron Pharmaceuticals by 60.1% in the 4th quarter. Rothschild Investment LLC now owns 975 shares of the biopharmaceutical company’s stock valued at $753,000 after purchasing an additional 366 shares in the last quarter. SBI Okasan Asset Management Co.Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $1,171,000. Finally, Moors & Cabot Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 10.1% in the 4th quarter. Moors & Cabot Inc. now owns 785 shares of the biopharmaceutical company’s stock valued at $606,000 after purchasing an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.0%

Shares of REGN opened at $621.52 on Friday. The stock has a market capitalization of $65.71 billion, a P/E ratio of 15.14, a PEG ratio of 1.39 and a beta of 0.30. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $721.74 and a two-hundred day simple moving average of $745.26. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $8.22 EPS. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group cut their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Barclays cut their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Leerink Partners reaffirmed a “market perform” rating and issued a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Finally, Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.